Evidence map›Paper›PMID 35286424›Full record

ReviewDer Radiologe2022

[Diagnostic imaging in multiple sclerosis].

Kirill Alektoroff, Panagiotis Papanagiotou

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Radiologe, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Kirill AlektoroffDepartment of Diagnostic and Interventional Neuroradiology, Klinikum Bremen-Mitte/Bremen-Ost, Bremen, Deutschland. alektoroff@gmx.de.
Panagiotis PapanagiotouDepartment of Diagnostic and Interventional Neuroradiology, Klinikum Bremen-Mitte/Bremen-Ost, Bremen, Deutschland.
Aretaeio Hospital · GRKlinikum Bremen-Mitte · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis (MS) is an inflammatory autoimmune disease that leads to the development of demyelination foci in the central nervous system and can affect any neurological function. In the developed world, it represents the most common chronic neurological (nontraumatic) disease in young and middle-aged patients. Magnetic resonance imaging (MRI) is the first-line imaging modality for the diagnosis and follow-up of MS. The currently valid McDonald criteria, updated in 2017, define the exact morphological imaging criteria for diagnosing MS. In addition to the detection of typical MS plaques, the determination of spatial and temporal dissemination is essential for the initial diagnosis. A standardized MRI protocol consisting of mandatory and optional sequences is recommended for reliable diagnosis and differentiation from a broad spectrum of differential diagnoses.

Indexed as

Multiple SclerosisCentral Nervous SystemDiagnosis, DifferentialHumansMagnetic Resonance ImagingMiddle AgedAutoimmune diseaseDemyelinating diseaseMagnetic resonance imagingMcDonald criteriaNervous system

Identifiers

PMID35286424
OpenAlexW4220902009

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.